Annual Accounts Receivable
$41.72 M
+$20.46 M+96.20%
December 31, 2024
Summary
- As of March 4, 2025, KNSA annual accounts receivable is $41.72 million, with the most recent change of +$20.46 million (+96.20%) on December 31, 2024.
- During the last 3 years, KNSA annual accounts receivable has risen by +$37.74 million (+947.03%).
- KNSA annual accounts receivable is now at all-time high.
Performance
KNSA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$41.72 M
+$16.84 M+67.65%
December 31, 2024
Summary
- As of March 4, 2025, KNSA quarterly accounts receivable is $41.72 million, with the most recent change of +$16.84 million (+67.65%) on December 31, 2024.
- Over the past year, KNSA quarterly accounts receivable has stayed the same.
- KNSA quarterly accounts receivable is now at all-time high.
Performance
KNSA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
KNSA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +96.2% | 0.0% |
| 3 y3 years | +947.0% | +947.0% |
| 5 y5 years | - | - |
KNSA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +947.0% | at high | +1272.0% |
| 5 y | 5-year | at high | -100.0% | at high | -100.0% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
Kiniksa Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $41.72 M(+96.2%) | $41.72 M(+67.6%) |
| Sep 2024 | - | $24.89 M(+21.7%) |
| Jun 2024 | - | $20.45 M(+27.9%) |
| Mar 2024 | - | $15.99 M(-24.8%) |
| Dec 2023 | $21.27 M(+68.0%) | $21.27 M(+599.3%) |
| Sep 2023 | - | $3.04 M(-87.7%) |
| Jun 2023 | - | $24.65 M(+232.0%) |
| Mar 2023 | - | $7.42 M(-41.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $12.66 M(+217.7%) | $12.66 M(+13.5%) |
| Sep 2022 | - | $11.16 M(+42.9%) |
| Jun 2022 | - | $7.81 M(-73.5%) |
| Mar 2022 | - | $29.44 M(+638.8%) |
| Dec 2021 | $3.98 M(>+9900.0%) | $3.98 M(+23.6%) |
| Sep 2021 | - | $3.22 M(+26.4%) |
| Jun 2021 | - | $2.55 M(>+9900.0%) |
| Dec 2020 | $0.00 | $0.00 |
FAQ
- What is Kiniksa Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals annual accounts receivable year-on-year change?
- What is Kiniksa Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Kiniksa Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of KNSA is $41.72 M
What is the all time high annual accounts receivable for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual accounts receivable is $41.72 M
What is Kiniksa Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, KNSA annual accounts receivable has changed by +$20.46 M (+96.20%)
What is Kiniksa Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of KNSA is $41.72 M
What is the all time high quarterly accounts receivable for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly accounts receivable is $41.72 M
What is Kiniksa Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, KNSA quarterly accounts receivable has changed by $0.00 (0.00%)